Tackling unmet needs in chronic myeloid leukaemia: What’s next in the treatment algorithm?

Access to this content is not permitted for healthcare professionals based in the UK, US or Japan

Back to Education
Leukaemia, Haematological Malignancies Watch Time: 62 mins

touchSATELLITE SYMPOSIUM Tackling unmet needs in chronic myeloid leukaemia: What’s next in the treatment algorithm?

Three experts consider unmet needs in chronic myeloid leukaemia and how new and emerging treatments may help address them.

Prof. Susanne Saussele

University Clinic, Mannheim, Germany


Prof. Massimo Breccia, Prof. Valentín García Gutiérrez
Watch Time: 04:13

Prof. Susanne Saussele opens the symposium and sets the scene for this discussion on tackling unmet needs in chronic myeloid leukaemia.

Watch Time: 21:47

Prof. Valentín García Gutiérrez presents a short overview of the toxicities associated with tyrosine kinase inhibitors for treating chronic myeloid leukaemia (CML) and the impact of these toxicities on patient management. The session concludes with a conversation between him and Prof. Saussele about managing patients with CML, which is structured around questions from the audience.

Watch Time: 10:35

Prof. Massimo Breccia highlights unmet needs in patients with chronic myeloid leukaemia (CML) being treated in the third- or later-line setting and how new and emerging treatments have been developed to address these unmet needs. The session concludes with a conversation between him and Prof. Saussele about which patients may benefit from the new and emerging therapies for CML, structured around questions from the audience.

Watch Time: 09:20

Prof. Susanne Saussele reviews the current treatment paradigm for chronic myeloid leukaemia, highlighting areas where new and emerging agents may have a role, as well as indicating therapeutic settings that remain challenging.

Watch Time: 16:06

Together with the audience, the expert panel discusses treatment options for three challenging case studies.

Leave Feedback
Overview & Learning Objectives

In this touchSATELLITE SYMPOSIUM, chronic myeloid leukaemia (CML) experts review the unmet treatment needs, including key safety considerations with tyrosine kinase inhibitors. They outline new and emerging agents and how they may address the unmet needs to improve outcomes for patients with CML.

Learning Objectives

After watching this activity, participants should be better able to:

  • Summarize the rationale for new agents in CML in light of treatment safety considerations
  • Discuss the unmet needs for patients with CML in later lines of therapy and how new agents may address these
  • Explain how new and emerging agents may affect the treatment paradigm for patients with CML
Faculty & Disclosures
Prof. Susanne Saussele

University Clinic, Mannheim, Germany

Prof. Susanne Saussele is head of the CML Excellence Center in Mannheim, Germany, including the molecular laboratory and the Study Centre for Hematology of the Mannheim Cancer Center. She is also chief resident of the polyclinic at the III. Medical Clinic, Hematology and Oncology, University Clinic, Mannheim. In 2017, she was appointed Professor at the University of Heidelberg. read more

Prof. Saussele is a project leader at EUTOS (EUropean Treatment and Outcome Study of CML) and E-MPN (European Myeloproliferative Neoplasms Network), and is a member of the ELN-CML (European LeukemiaNet Chronic Myeloid Leukemia) working party. In addition, she is a member of the Scientific Program Committee of DGHO (German Society for Hematology and Medical Oncology) and was a member of the Scientific Program Committee of EHA (European Hematology Association) from 2014 to 2019.

Prof. Susanne Saussele discloses: Grants/Research support from Bristol Myers Squibb, Incyte and Novartis. Honoraria from Bristol Myers Squibb, Incyte, Novartis, Pfizer and Roche.

Prof. Massimo Breccia

Sapienza University of Rome, Rome, Italy

Prof. Massimo Breccia is an associate professor at Sapienza University of Rome, Azienda Policlinico Umberto I, Italy, where he is head of the Day Hospital Unit. read more

His scientific interests and publications are mainly focused on the biological and clinical aspects of acute and chronic myeloid leukaemias and myelodysplastic syndromes.

Prof. Breccia is a member of the SIE (Italian Society of Hematology), SIES (Italian Society of Experimental Hematology) and EHA (European Hematology Association). He is also co-chair of the GIMEMA QoL (Italian Adult Haematological Diseases Group – Quality of Life) working party and elected member of the GIMEMA MPN (myeloproliferative neoplasms) working party.

Prof. Breccia is an investigator in several clinical trials – particularly phase I – for chronic myeloid leukaemia, acute myeloid leukaemia and myelodysplastic syndromes. He has authored more than 500 peer-reviewed publications and serves as a peer reviewer for several journals, such as Blood, The Lancet, The Lancet Haematology, Haematologica, British Journal of Haematology and Cancer. He is also a member of the editorial board or associate editor of journals such as Frontiers in Oncology and Cancers.

Prof. Massimo Breccia discloses: Honoraria from AbbVie, Bristol Myers Squibb/Celgene, Incyte, Novartis and Pfizer.

Prof. Valentín García Gutiérrez

Ramón y Cajal University Hospital Madrid, Spain

Prof. Valentín García Gutiérrez is a haematologist at the Ramón y Cajal University Hospital and an associate professor of medicine at the University of Alcalá, Alcalá de Henares, Madrid, Spain.  read more

He has been a principal investigator on 25 clinical trials (phases I–IV),  investigating chronic myeloproliferative disorders and bone marrow transplantation. He is a principal investigator of the ‘Grupo de Hematología Traslacional’ at IRYCIS (the Ramón y Cajal Institute for Health Research). He also coordinates a number of national clinical trials in chronic myeloid leukaemia.

Prof. García Gutiérrez’s research has appeared in over 100 international publications and he has also contributed to a number of national guidelines and book chapters. He is a frequent invited lecturer at international and national haematology congresses. He is also president of GELMC (Spanish Chronic Myeloid Leukemia Group) and a member of GEMFIN (Spanish Group for Philadelphia Chromosome Negative Myeloproliferative Neoplasms).

Prof. Valentín García Gutiérrez discloses: Advisory fees from Bristol Myers Squibb, Incyte, Novartis and Pfizer. Honoraria from Bristol Myers Squibb, Incyte, Novartis and Pfizer. Research funding from Bristol Myers Squibb, Incyte and Pfizer. Speaker fees from Novartis.


View and download resources from this activity to support your learning and share with colleagues

  • 1000+ topical and insightful peer-reviewed journal articles
  • 100+ hours of bite-sized congress highlights
  • 8 major therapy areas packed with the latest scientific advances
  • 150+ specialties offering learn-on-the-go medical education
  • + Concise email updates and newsletters so you never miss out
Register For Free Now
Feedback Close

Please provide feedback for this touchSATELLITE SYMPOSIUM on the following
(scale 1-5, 1 strongly disagree; 5 strongly agree):

* = Mandatory Field

Feedback Close
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72